Prophylactic / therapeutic agent for pregnancy-induced hypertension

The APA-Fc fusion protein, with APA linked to an immunoglobulin Fc region via a peptide linker, addresses the limitations of existing antihypertensive drugs by preventing placental penetration and providing stable, long-lasting maternal blood pressure reduction without fetal harm, effectively treating pregnancy-induced hypertension.

WO2024237199A1PCT designated stage expired Publication Date: 2024-11-21KANAZAWA UNIV +3
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017419
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current antihypertensive drugs for pregnancy-induced hypertension are ineffective in safely lowering maternal blood pressure without adverse effects on the fetus, as they penetrate the placental barrier and have limited stability and safety concerns.

Method used

Development of an APA-Fc fusion protein where aminopeptidase A (APA) is linked to an immunoglobulin Fc region via a peptide linker, creating a high molecular weight protein that mimics natural placental functions, preventing placental penetration and providing stable, long-lasting antihypertensive effects.

Benefits of technology

The APA-Fc fusion protein effectively degrades angiotensin II, safely lowering maternal blood pressure with minimal side effects, while maintaining fetal safety by avoiding placental transfer and offering prolonged therapeutic action.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017419_21112024_PF_FP_ABST
    Figure JP2024017419_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing a prophylactic and / or therapeutic agent for hypertensive disorders of pregnancy, which has a physical property or a molecular weight that inhibits the passage through the placental barrier, has a pharmacological activity that mimics the original physiological function of the placenta and therefore has fewer adverse side effects, is safe for a mother body and a fetus, is stable for a long period, and can exert the efficacy thereof in vivo for a long period. The present invention is a prophylactic / therapeutic agent for pregnancy-induced hypertension, which contains aminopeptidase A (APA) as an active ingredient, the prophylactic / therapeutic agent being characterized in that the APA is bound to an immunoglobulin Fc region through a peptide linker.
Need to check novelty before this filing date? Find Prior Art

Description

Preventive / therapeutic agent for pregnancy-induced hypertension

[0001] The present invention relates to an aminopeptidase A (APA)-Fc fusion protein and a preventive / therapeutic agent for pregnancy-induced hypertension containing the same.

[0002] Pregnancy-induced hypertension is said to occur in as many as one in five pregnant women, and is a disease that requires careful attention, as it is particularly prone to becoming severe in early-onset cases that occur before the 34th week of pregnancy. If the condition becomes severe, it can cause elevated blood pressure, proteinuria, seizures (eclampsia), cerebral hemorrhage, and liver and kidney dysfunction, making it a fatal disease for the mother. Pregnancy-induced hypertension can also cause serious symptoms for the fetus, including fetal growth restriction, fetal dysfunction, and placental abruption, making it a serious disease for both the mother and the fetus.

[0003] Treatment for pregnancy-induced hypertension primarily involves bed rest and hospitalization, and there is no fundamental cure for the disease. Early termination of pregnancy is considered the best treatment. While recent advances in neonatal intensive care units (NICUs) have made it possible to deliver extremely low birth weight babies weighing less than 1,000 grams, early termination of pregnancy means premature termination of fetal development. Extremely low and low birth weight babies are at increased risk of various respiratory, circulatory, digestive, and neurological complications, as well as a higher risk of developmental disorders later in life. In other words, early termination of pregnancy is never desirable, even if it is intended to protect the mother and fetus from the serious disease known as pregnancy-induced hypertension.

[0004] While antihypertensive drugs are commonly used to lower blood pressure, the "2021 Guidelines for the Management of Pregnancy-Induced Hypertension" states that "there is limited evidence regarding the safety and effectiveness of antihypertensive drugs for the mother and child." While the guidelines recommend methyldopa, labetalol, nifedipine, and hydralazine for pregnancy-induced hypertension, they pose caveats regarding side effects and administration methods, urging careful administration. Furthermore, these antihypertensive drugs are low-molecular-weight compounds with molecular weights of less than 400, which penetrate the placental barrier and act on the fetal-placental circulatory system, impairing fetal-placental blood flow (reducing fetal blood pressure). The administration of conventional antihypertensive drugs simply places stress on the fetus, preventing fetal well-being.

[0005] Meanwhile, research into the mechanism of onset of pregnancy-induced hypertension has been progressing (Non-Patent Document 1). Non-Patent Document 1 explains the mechanism of onset of pregnancy-induced hypertension as follows: To maintain its own circulatory system, the fetus maintains its blood pressure by secreting vasopressin and angiotensin II from the pituitary gland. If excessive amounts of fetal vasopressin or angiotensin II are released into the mother's blood, maternal blood pressure rises, resulting in hypertension. Angiotensin II is degraded in the placenta and pregnant woman's blood by aminopeptidase A (APA), which is abundantly expressed in the placenta and released into maternal blood, preventing excessive angiotensin II from leaking outside the placental barrier (to the mother's side). Furthermore, the secretion of angiotensin II is promoted as the fetus grows, and APA secretion is also promoted accordingly, so that it acts as a fetal growth factor that maintains the placental barrier function. Furthermore, the concentration of angiotensin II, which is essential for maintaining the fetal-placental circulatory system, is always higher on the fetal side than on the maternal side. However, when APA activity in the placenta and pregnant woman's blood decreases, angiotensin II that cannot be completely broken down leaks into the maternal blood. This leakage of angiotensin II into the mother is thought to raise the mother's blood pressure and cause pregnancy-induced hypertension.

[0006] Therefore, attempts have been made to treat pregnancy-induced hypertension by administering APA protein to enhance the decreased APA activity in placenta and maternal blood (Patent Document 1, Non-Patent Document 2). However, in a study in which APA protein was administered to spontaneously hypertensive rats, the blood pressure-lowering effect disappeared approximately 3 to 24 hours after administration of the APA protein, necessitating daily administration of the APA protein. Furthermore, in the prior art (Patent Document 1, Non-Patent Document 2), APA was produced by incorporating DNA encoding APA into a baculovirus and infecting Sf-9 cells. Sf-9 cells are insect-derived cells, and because glycosylation of proteins differs from that of mammalian cells, there was a possibility of immunogenicity.

[0007] In light of the above, a more ideal therapeutic agent for preeclampsia would be one that does not penetrate the placental barrier, reliably lowers blood pressure in the mother while being safe for both the mother and fetus, and whose effects are stable and sustained; however, no such antihypertensive drug currently exists.

[0008] Japanese Patent Application Laid-Open No. 2007-217395

[0009] Obstetrics and Gynecology Practice, 1995, vol. 44, pp. 1819-1827 Journal of Biomedicine and Biotechnology, vol. 2011, Article ID286947, 12 pages

[0010] In the circumstances described above, the present invention aims to provide an agent for the prevention and / or treatment of pregnancy-induced hypertension, which has physical properties or molecular weight that prevent it from passing through the placental barrier, has pharmacological effects that mimic the original physiological functions of the placenta, and thereby has few side effects, is safe for the mother and fetus, and is stable for a long period of time and can exert its effectiveness in the body for a long period of time.

[0011] To solve the above problems, the present inventors conducted extensive research into the addition of globulin protein to recombinant APA expressed in high yields in mammalian cells to ensure sufficient molecular weight. As a result, they discovered an optimal globulin protein for adding to APA to ensure efficacy and stability. Furthermore, they discovered that adding the globulin protein via a linker having a specific sequence and a certain length, rather than directly to APA, results in a prophylactic and / or therapeutic agent for pregnancy-induced hypertension that is stable for a long period of time, can exert its efficacy in the body for a long period of time, and also has excellent angiotensin II degradation activity. The gist of the present invention is as follows.

[0012] [1] A preventive / therapeutic agent for pregnancy-induced hypertension, comprising aminopeptidase A (APA) as an active ingredient, wherein the APA is linked to an immunoglobulin Fc region via a peptide linker. [2] The preventive / therapeutic agent for pregnancy-induced hypertension according to [1], wherein the peptide linker consists of 5 to 60 amino acids. [3] The preventive / therapeutic agent for pregnancy-induced hypertension according to [1] or [2], wherein the peptide linker comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 4 to 9. [4] The preventive / therapeutic agent for pregnancy-induced hypertension according to [3], further comprising a pharmaceutically acceptable carrier. [5] An APA-Fc fusion protein, wherein aminopeptidase A (APA) is linked to an immunoglobulin Fc region via a peptide linker comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 10 to 12. [6] The APA-Fc fusion protein according to [5], having the amino acid sequence set forth in SEQ ID NO: 11.

[0013] The present invention provides a preventive and / or therapeutic agent for pregnancy-induced hypertension, which has physical properties or molecular weight that prevent it from penetrating the placental barrier, has pharmacological effects that mimic the inherent physiological functions of the placenta, and is therefore safe for both the mother and fetus, stable for extended periods, and effective in the body for extended periods. Furthermore, attempts to attach globulin proteins to recombinant proteins via linkers have been put to practical use in protein pharmaceuticals that target specific receptors and act by binding to them. However, the enzymes targeted by the present invention require a completely different linker introduction strategy from previous protein pharmaceuticals, since enzyme activity is affected by the affinity and accessibility to catalytic sites, which differ for each substrate. The present invention provides a linker introduction strategy for enzymes and globulin proteins by evaluating enzyme activity using physiological substrates.

[0014] FIG. 1 shows a scheme of the present invention. A recombinant APA-Fc fusion protein, in which APA, which hydrolyzes angiotensin, which has a blood pressure-increasing effect by constricting blood vessels, is bound to immunoglobulin, has low fetal transfer due to its high molecular weight, and can be used as a safe antihypertensive drug for pregnancy-induced hypertension. FIG. 2 shows the results of measuring the substrate hydrolysis activity of various APA-Fc fusion proteins. FIG. 3 shows the results of measuring the Glu-MCA hydrolysis activity of various APA-Fc fusion proteins. FIG. 4 shows the time course of plasma concentrations of various APA-Fc fusion proteins in mice. FIG. 5 shows a scheme for an experiment evaluating the antihypertensive effect of various APA-Fc fusion proteins in hypertension-induced mice. FIG. 6 shows the time course of systolic blood pressure after administration of various APA-Fc fusion proteins to hypertension-induced mice. FIG. 7 shows the antihypertensive effect of rhAPA-Fc administration in pregnancy-induced hypertension mice.

[0015] The APA-Fc fusion protein, which is an agent for preventing / treating pregnancy-induced hypertension of the present invention, will be described in detail below.

[0016] DEFINITIONS The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to a polymer of amino acids. In various embodiments, a "peptide," "polypeptide," and "protein" is a chain of amino acids in which the alpha carbons are linked through peptide bonds. The terminal amino acid at one end of the chain (the amino terminus) has a free amino group, while the terminal amino acid at the other end of the chain (the carboxy terminus) has a free carboxyl group.

[0017] As used herein, "peptides," "polypeptides," and "proteins" encompass "peptides," "polypeptides," and "proteins" that have been modified in any way and for any reason, such as to reduce susceptibility to proteolysis, reduce susceptibility to oxidation, change binding affinity for the purpose of protein complex formation, change binding affinity, and to impart or modify other physicochemical or functional properties. For example, a single amino acid substitution (e.g., conservative amino acid substitution) or multiple amino acid substitutions may be made in the native sequence (e.g., in the portion of the polypeptide outside the domains that form intermolecular contacts). A "conservative amino acid substitution" refers to the substitution of an amino acid in a peptide with a functionally similar amino acid. Each of the following six groups contains amino acids that are functionally similar to each other.

[0018] (1) Alanine (A), Serine (S), and Threonine (T) (2) Aspartic Acid (D) and Glutamic Acid (E) (3) Asparagine (N) and Glutamine (Q) (4) Arginine (R) and Lysine (K) (5) Isoleucine (I), Leucine (L), Methionine (M), and Valine (V) (6) Phenylalanine (F), Tyrosine (Y), and Tryptophan (W)

[0019] As used herein, the term "polynucleotide" is used interchangeably with "nucleic acid," "gene," or "nucleic acid molecule," and refers to a polymer of nucleotides. As used herein, the term "nucleotide sequence" is used interchangeably with "nucleic acid sequence" or "base sequence," and is represented as a sequence of deoxyribonucleotides (abbreviated as A, G, C, and T). For example, a "polynucleotide comprising the nucleotide sequence of SEQ ID NO: 1 or a fragment thereof" refers to a polynucleotide or a fragment thereof comprising the sequence represented by each of the deoxynucleotides A, G, C, and / or T of SEQ ID NO: 1.

[0020] As used herein, "Fc region" defines the C-terminal region of an immunoglobulin heavy chain, which can be generated by papain digestion of an intact antibody. The Fc region may be a native-sequence Fc region or a variant Fc region. The Fc region of an immunoglobulin typically contains two constant domains, a CH2 domain and a CH3 domain, and optionally contains a CH4 domain.

[0021] As used herein, the term "linker" refers to a molecule that links two molecules together covalently or through an ionic, van der Waals, or hydrogen bond. For example, the term also includes a nucleic acid molecule that hybridizes to the 5'-end of one complementary sequence and to the 3'-end of another complementary sequence, thereby linking two non-complementary sequences.

[0022] As used herein, a "vector" is a polynucleotide that can be used to introduce another nucleic acid linked to it into a cell. One type of vector is a "plasmid," which is a linear or circular double-stranded DNA molecule into which additional nucleic acid segments can be ligated. Another type of vector is a viral vector (e.g., replication-deficient retroviruses, replication-deficient adenoviruses, and replication-deficient adeno-associated viruses), whose viral genome can incorporate additional DNA segments. Certain vectors are capable of autonomous replication within the host cell into which they are introduced (e.g., bacterial vectors containing a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell after introduction and are replicated along with the host genome. An "expression vector" is a type of vector that can direct the expression of a selected polynucleotide.

[0023] <Preventive / Treatment Agent for Pregnancy-Induced Hypertension> The preventive / therapeutic agent for pregnancy-induced hypertension (preventive and / or therapeutic agent) of the present invention is a preventive / therapeutic agent for pregnancy-induced hypertension containing aminopeptidase A (APA) as an active ingredient, characterized in that the APA is linked to an immunoglobulin Fc region via a peptide linker (APA-Fc fusion protein). In the preventive / therapeutic agent for pregnancy-induced hypertension of the present invention, the APA is linked to an immunoglobulin Fc region via a peptide linker, so that its molecular weight is sufficiently large and it does not penetrate the placental barrier when administered to a pregnant woman, eliminating the risk of adverse effects on the fetal and placental circulatory system. Furthermore, APA metabolically degrades the vasoconstrictor peptide angiotensin II to angiotensin III, thereby effectively lowering mean blood pressure and making it suitable for use as a preventive / therapeutic agent for pregnancy-induced hypertension. Furthermore, the preventive / therapeutic agent for pregnancy-induced hypertension of the present invention contains, as an active ingredient, APA protein, which is present in large amounts in human blood and organs, and is produced in mammalian cells, so there is almost no possibility of antibodies being produced when administered to humans, and therefore side effects on the human body are extremely minimal.

[0024] The agent for preventing / treating pregnancy-induced hypertension of the present invention may contain, in addition to the APA-Fc fusion protein (a protein having a structure in which APA is bound to an immunoglobulin Fc region via a peptide linker) contained as an essential component, other components within the scope of not impairing the effects of the present invention. The APA-Fc fusion protein and other components are described below.

[0025] [APA-Fc Fusion Protein] The APA-Fc fusion protein contained in the agent for preventing / treating pregnancy-induced hypertension of the present invention is a fusion protein having a structure of (APA)-(linker)-(Fc), in which aminopeptidase A (APA) is linked to the immunoglobulin Fc region via a peptide linker.

[0026] In the present invention, aminopeptidase A (APA), also known as angiotensinase, is an enzyme that metabolically degrades the vasoconstrictor peptide angiotensin II to angiotensin III. The APA in the APA-Fc fusion protein is preferably human APA. Furthermore, the APA is preferably one that has been converted from its original membrane-bound form to an extracellularly secreted form by substituting a specific region at the N-terminus of human APA with a signal peptide. Specifically, for example, it is preferable to use human APA in which 71 amino acids from the N-terminus have been substituted with the signal peptide of SEQ ID NO: 1 (i.e., the signal peptide of human trypsin II) (rhAPA; recombinant human APA). Such an APA converted to an extracellularly secreted form preferably has the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having at least 90%, 95%, or 98% sequence identity thereto.

[0027] The immunoglobulin Fc region (Fc) in the APA-Fc fusion protein of the present invention is preferably an IgG Fc region, and may be any of IgG1, IgG2, IgG3, and IgG4. Furthermore, the Fc region preferably contains one or more amino acid deletions, additions, and / or substitutions that reduce or eliminate Fc receptor binding and / or Fc region effector functions. Specifically, an example of the immunoglobulin Fc region (Fc) in the APA-Fc fusion protein of the present invention is the amino acid sequence of an IgG1 immunoglobulin Fc region set forth in SEQ ID NO:3. Here, the sequence shown in SEQ ID NO: 3 preferably includes an amino acid substitution corresponding to P329 of the wild-type human IgG1 Fc region, specifically a substitution corresponding to P329G, and at least one additional amino acid substitution, and even more preferably includes amino acid substitutions corresponding to P329, L234, and L235 of the wild-type human IgG1 Fc region, specifically substitutions corresponding to P329G, L234A, and L235A, respectively. In SEQ ID NO: 3, the amino acids corresponding to P329, L234, and L235 of the wild-type human IgG1 Fc region are P at position 109, and L at positions 14 and 15, respectively, in SEQ ID NO: 3. The immunoglobulin Fc region (Fc) in the APA-Fc fusion protein of the present invention also includes those having amino acid sequences that share at least 90%, 95%, or 98% sequence identity with these sequences.

[0028] The peptide linker linking the APA and the immunoglobulin Fc region is preferably a flexible linker having a specific sequence and a certain length, and is preferably a linker consisting of 5 to 60 amino acids, more preferably a linker consisting of 5 to 30 amino acids, and even more preferably a linker consisting of 5 to 20 amino acids. Specifically, examples of linkers include those containing GGGGS ((G4S), SEQ ID NO: 4), GGGGSGGGGS ((G4S)2, SEQ ID NO: 5), GGGGSGGGGSGGGGGS ((G4S)3, SEQ ID NO: 6), EAAAK ((EA3K), SEQ ID NO: 7), EAAAKEAAAK ((EA3K)2, SEQ ID NO: 8), EAAAKEAAAKEAAAK ((EA3K)3, SEQ ID NO: 9), etc., and linkers containing GGGGS (SEQ ID NO: 4), GGGGSGGGGSGGGGGS (SEQ ID NO: 6), or EAAAKEAAAKEAAAK (SEQ ID NO: 9) are preferred, and linkers containing GGGGSGGGGGSGGGGGS ((G4S)3, SEQ ID NO: 6) are more preferred. As the peptide linker, a linker which is GGGGS ((G4S), SEQ ID NO: 4), GGGGSGGGGS ((G4S)2, SEQ ID NO: 5), GGGGSGGGGSGGGGGS ((G4S)3, SEQ ID NO: 6), EAAAK ((EA3K), SEQ ID NO: 7), EAAAKEAAAK ((EA3K)2, SEQ ID NO: 8), EAAAKEAAAKEAAAK ((EA3K)3, SEQ ID NO: 9) is preferred, a linker which is GGGGS (SEQ ID NO: 4), GGGGSGGGGSGGGGGS (SEQ ID NO: 6), or EAAAKEAAAKEAAAK (SEQ ID NO: 9) is more preferred, and a linker which is GGGGSGGGGGSGGGGGS ((G4S)3, SEQ ID NO: 6) is even more preferred.

[0029] The APA-Fc fusion protein of the present invention is not limited to those having specific amino acid sequences as long as each component of (APA)-(linker)-(Fc) has the above-mentioned characteristics, and examples thereof include those having the amino acid sequences represented by SEQ ID NOs: 10 to 12.

[0030] [Method for Producing APA-Fc Fusion Protein] In the present invention, the APA-Fc fusion protein can be produced by a method known to those skilled in the art. That is, a polynucleotide encoding the APA-Fc fusion protein in which the above-mentioned APA, peptide linker, and Fc region are fused is introduced into an expression vector, an appropriate host cell is transformed with this expression vector, the APA-Fc fusion protein is produced, and the APA-Fc fusion protein can be obtained by purification.

[0031] The polynucleotide encoding the APA-Fc fusion protein may be operably linked to one or more regulatory nucleotide sequences within an expression construct. Regulatory sequences are art-recognized and are selected to promote expression of the APA-Fc fusion protein. Thus, the term "regulatory sequence" encompasses promoters, enhancers, and other expression control elements. Typically, regulatory sequences include, but are not limited to, promoter sequences, leader or signal sequences, ribosomal binding sites, transcription start and stop sequences, translation start and stop sequences, and enhancer or activator sequences. Constitutive or inducible promoters known in the art may be used. The promoter may be a native promoter or a hybrid promoter that combines elements of two or more promoters. The expression construct may be present intracellularly or episomally, such as a plasmid, or the expression construct may be inserted chromosomally. In various embodiments, the expression vector contains a selectable marker gene to allow for the selection of transformed host cells. Selectable marker genes are known in the art and vary depending on the host cell used.

[0032] The polynucleotide encoding the APA-Fc fusion protein is provided in an expression vector comprising a nucleotide sequence operably linked to at least one regulatory sequence. An expression vector refers to a plasmid, phage, virus, or vector for expressing a polypeptide from a polynucleotide sequence. Suitable vectors for expression in host cells are readily available, and insertion of nucleic acid molecules into the vector is performed using standard recombinant DNA techniques. Such vectors can contain various expression control sequences that regulate expression of DNA sequences when operably linked to them. Useful expression control sequences include, for example, the immediate-early promoters of cytomegalovirus or adenovirus, the early and late promoters of SV40, the tet promoter, the RSV promoter, the lac system, the trp system, the TAC system, or the TRC system, the T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage lambda, the regulatory region for the fd coat protein, promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoter for acid phosphatase (e.g., PhoS), the promoter for yeast alpha mating factor, the polyhedrin promoter of baculovirus systems, and other sequences known to regulate the expression of genes in prokaryotic or eukaryotic cells or their viruses, as well as various combinations thereof. The design of the expression vector can vary depending on factors such as the choice of the host cell to be transformed and / or the type of protein desired to be expressed. Furthermore, the copy number of the vector, the ability to control that copy number, and the expression of any other proteins encoded by the vector (such as antibiotic markers) should also be considered, as appropriate.

[0033] Some mammalian expression vectors contain both prokaryotic sequences that facilitate propagation of the vector in bacteria and one or more eukaryotic transcription units that are expressed in eukaryotic cells. pcDNAI / amp-derived vectors, pcDNAI / neo-derived vectors, pRc / CMV-derived vectors, pSV2gpt-derived vectors, pSV2neo-derived vectors, pSV2-dhfr-derived vectors, pTk2-derived vectors, pRSVneo-derived vectors, pMSG-derived vectors, pSVT7-derived vectors, pko-neo-derived vectors, and pHyg-derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors have been modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, for transient expression of proteins in eukaryotic cells, derivatives of viruses such as bovine papillomavirus (BPV-1) or Epstein-Barr virus (pHEBo, pREP-derived, and p205) can be used. Various methods employed in the preparation of plasmids and transformation of host cells are well known in the art. In some cases, baculovirus expression systems may be used to express recombinant polypeptides. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393, and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the B-gal-containing pBlueBacIII).

[0034] The cells for expressing and producing the APA-Fc fusion protein of the present invention are not particularly limited, but preferred examples include Expi293F cells and CHO cells. Examples of vectors for this purpose include the Pcmv-Script vector (Stratagene, La Jolla, California), the pcDNA4 vector (Invitrogen, Carlsbad, California), and the pCI-neo vector (Promega, Madison, Wisconsin). The APA-Fc fusion protein can be expressed and produced in CHO cells grown in culture medium, followed by purification.

[0035] The APA-Fc fusion proteins of the present invention can be purified according to protein purification methods well known to those of skill in the art. Partial or complete purification (i.e., purification to homogeneity) can be achieved by purification methods such as chromatography and electrophoresis. Various methods suitable for purification are well known to those of skill in the art. These methods include, for example, precipitation using ammonium sulfate, PEG, antibodies (immunoprecipitation), or heat denaturation, followed by centrifugation; chromatography, such as affinity chromatography (protein A column), ion exchange chromatography, gel filtration chromatography, reversed-phase chromatography, hydroxyapatite chromatography, and hydrophobic interaction chromatography; isoelectric focusing; gel electrophoresis; and combinations of these methods.

[0036] [Other Optional Components] The agent for the prophylaxis / treatment of pregnancy-induced hypertension of the present invention may further contain a pharmaceutically acceptable carrier. Such pharmaceutically acceptable carriers are well known to those skilled in the art and may be included for the purpose of changing, maintaining, or preserving the pH, osmolarity, viscosity, transparency, color, isotonicity, odor, sterility, stability, dissolution rate, release rate, adsorption, permeability, etc. of the agent for the prophylaxis / treatment of pregnancy-induced hypertension of the present invention.Preferred carriers include amino acids (such as glycine, glutamine, asparagine, arginine, or lysine); antimicrobial agents; antioxidants (such as ascorbic acid, sodium sulfite, or sodium bisulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrate, phosphate, other organic acids, etc.); bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediaminetetraacetic acid (EDTA)), complexing agents (such as caffeine, polyvinylpyrrolidone, β-cyclodextrin, or hydroxypropyl-β-cyclodextrin), fillers; monosaccharides; disaccharides and other carbohydrates (such as glucose, mannose, or dextrin); proteins (such as serum albumin, gelatin, or immunoglobulins); colorants; flavoring agents, and diluents. agent); emulsifier; hydrophilic polymer (such as polyvinylpyrrolidone); low molecular weight polypeptide; salt-forming counterion (such as sodium); preservative (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or hydrogen peroxide); solvent (such as glycerin, propylene glycol, or polyethylene glycol); sugar alcohol (such as mannitol or sorbitol); suspending agent; surfactant or wetting agent (such as Pluronic®, PEG, sorbitan ester, polysorbate, e.g., polysorbate 20, polysorbate 80, Triton, tromethamine, lecithin, cholesterol, tyloxapal, etc.); stabilizer (sucrose or sorbitol); tonicity enhancing agent Examples of suitable additives include, but are not limited to, alkali metal halides (preferably sodium or potassium chloride, mannitol, sorbitol, etc.); delivery vehicles; diluents; excipients, and / or pharmaceutical adjuvants.

[0037] The primary solvent or carrier in the agent for preventing / treating pregnancy-induced hypertension of the present invention may be essentially aqueous or non-aqueous. For example, a suitable solvent or carrier may be distilled water for injection or physiological saline, to which other substances typically contained in compositions for parenteral administration may be added. Examples of solvents include neutral buffered saline or physiological saline mixed with serum albumin. Other solvents include Tris buffer solution of about pH 7.0 to 8.5 or acetate buffer solution of about pH 4.0 to 5.5, which may further contain sorbitol or a suitable substitute thereof. Furthermore, the agent for preventing / treating pregnancy-induced hypertension of the present invention may be formulated as a lyophilized product using appropriate pharmaceutical excipients such as sucrose. The optimal pharmaceutical composition can be determined by those skilled in the art based on the intended route of administration, delivery mode, and desired dose.

[0038] The agent for preventing / treating pregnancy-induced hypertension of the present invention can be produced by a method known to those skilled in the art, such as by mixing the above-mentioned optional ingredients with the APA-Fc fusion protein, which is an essential ingredient.

[0039] [Dosage and Administration] The effective amount of the agent for preventing / treating pregnancy-induced hypertension of the present invention used therapeutically varies depending on the type and purpose of the prevention / treatment. That is, the appropriate dose level for treatment will vary, in part, depending on the molecule to be delivered, the route of administration of the polypeptide, and the patient's size (body weight, body surface, or organ size) and condition (age and overall health). Therefore, dosage adjustment and modification of the route of administration can be performed to achieve optimal therapeutic effects. Typical doses range from about 0.0001 mg / kg to about 100 mg / kg or more of APA-Fc fusion protein, depending on the factors described above. Preferably, the agent for preventing / treating pregnancy-induced hypertension of the present invention may be injected or administered intravenously. Depending on the half-life and clearance rate of the formulation, it may be administered daily, every 1-2 days, every 3-4 days, weekly, every other week, or monthly. The administration frequency will depend on the pharmacokinetic parameters of the polypeptide in the formulation used. Typically, it is administered until a dose that achieves the desired effect is reached. The preventive / therapeutic agent for pregnancy-induced hypertension of the present invention may be administered as a single dose, or as multiple doses over a long period of time (at the same or different concentrations per dose), or as a continuous infusion. Further refinement of the appropriate dosage is performed periodically. Appropriate doses may be confirmed using appropriate dose-response data.

[0040] Specific administration routes for the preventive / therapeutic agents for pregnancy-induced hypertension of the present invention are in accordance with known methods, such as oral, intravenous, intraperitoneal, intratumoral, intracerebral (intracerebroparenchymal), intraventricular, intramuscular, intraocular, intraarterial, intraportal, or intralesional injection, intramedullary, intrathecal, intravesical, intraventricular, transdermal, subcutaneous, or intraperitoneal administration; as well as intranasal, enteral, topical, sublingual, transurethral, ​​vaginal, or rectal administration, sustained-release systems, or implanted devices. If desired, administration may be by bolus administration, continuous infusion, or implanted device. Alternatively, administration may be topical via implantation of a membrane, sponge, or other suitable material to which the target molecule is adsorbed or encapsulated. Where an implantation device is used, the device may be implanted in any suitable tissue or organ, and delivery of the molecule of interest may be via diffusion, timed-release bolus, or continuous administration.

[0041] <APA-Fc Fusion Protein> The present invention also includes an APA-Fc fusion protein in which aminopeptidase A (APA) is linked to an immunoglobulin Fc region via a peptide linker comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 4 to 9. In the APA-Fc fusion protein of the present invention, aminopeptidase A (APA) is preferably linked to an immunoglobulin Fc region via a peptide linker comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 4 to 9. The APA-Fc fusion protein of the present invention has physical properties or a molecular weight that prevent it from passing through the placental barrier, and has pharmacological effects that mimic the inherent physiological functions of the placenta, resulting in few side effects, safety for the mother and fetus, and prolonged stability and long-lasting efficacy in the body. Therefore, it is suitable for use as an active ingredient in an agent for preventing and / or treating pregnancy-induced hypertension. The description in the section on the agent for preventing and / or treating pregnancy-induced hypertension applies to the APA-Fc fusion protein of the present invention as is.

[0042] <Polynucleotide Encoding APA-Fc Fusion Protein> The present invention also includes a polynucleotide encoding the above-described APA-Fc fusion protein. The APA-Fc fusion protein can be produced by introducing a polynucleotide encoding the above-described APA-Fc fusion protein in which the APA, peptide linker, and Fc region are fused into an expression vector and transforming an appropriate host cell with this expression vector. Note that the explanation in the section regarding the preventive and / or therapeutic agent for pregnancy-induced hypertension can be applied as is to the APA-Fc fusion protein of the present invention.

[0043] The present invention will be described in detail below with reference to examples and test examples, but the present invention is not limited to these examples.

[0044] [Test 1] Preparation of APA-Fc fusion protein A plasmid was prepared by inserting a base sequence encoding the prepro-trypsin leader peptide (MSALLILALVGAAVA), human APA starting from Ala72, and the Fc region of human IgG1 into the pCAGGS vector. 2 2.5 × 10 cells were cultured in Expi293 Expression Medium (Life Technologies Japan, Inc.) under a shaking speed of 125 rpm. 6 Various plasmids were introduced into Expi293F cells (Life Technologies Japan, Inc.) at 1000 cells / mL using an ExpiFectamine 293 Transfection Kit (Life Technologies Japan, Inc.). The cells were cultured for 5 days, allowing the APA-Fc fusion protein to be secreted into the cell culture medium. The cell culture medium was centrifuged at 4°C and 6,300 g for 10 minutes, and the resulting supernatant was passed through a PVDF Millex-GV filter (0.22 μm pore size filter, Merck Co., Ltd.), and the filtrate was subjected to affinity column purification.

[0045] MonoSpin ProA (GL Sciences Inc.) was conditioned by passing 5 mL of binding buffer (150 mM sodium chloride, 50 mM sodium phosphate buffer (pH 7.0)). The filtrate was passed through the column, and the APA-Fc fusion protein was retained on the column. The column was washed with 5 mL of wash buffer (1 M sodium chloride, 50 mM sodium phosphate buffer (pH 7.0)), and then 1 mL of elution buffer (100 mM glycine buffer (pH 3.5)) was passed five times to elute the APA-Fc fusion protein from the column. The eluate was quickly mixed with 0.1 mL of neutralization buffer (1 M trishydroxymethylaminomethane buffer) to neutralize it. The neutralized eluate was sealed in a dialysis membrane (Spectrapore, molecular weight cutoff: 140,000) and then stirred in 1 L of phosphate-buffered saline (PBS) at 4°C three times to replace the APA-Fc fusion protein solution with PBS. The protein concentration in the APA-Fc fusion protein solution was measured using a BCA Protein Assay Kit (Life Technologies Japan, Inc.) with bovine serum albumin as a standard solution.

[0046] [Test 2] Measurement of substrate hydrolysis activity of various APA-Fc fusion proteins (1) Angiotensin II hydrolysis activity In a buffer (pH 7.5) containing 25 mM trishydroxymethylaminomethane, 1 mM calcium chloride, and 0.01% bovine serum albumin, 1.5 or 15 μg / mL APA-Fc fusion protein was incubated with 10 μM angiotensin II (Peptide Institute, Inc.) at 37 °C, and the reaction was stopped by adding 2 volumes of cold methanol to the supernatant. After centrifugation at 4 °C and 21,500 g for 10 minutes, 4.5 volumes of water were added to the supernatant, which was then centrifuged again at 21,500 g for 10 minutes. The centrifuged supernatant was subjected to measurement using a liquid chromatography-triple quadrupole mass spectrometer (LCMS-8040, Shimadzu Corporation). The column was a COSMOSIL 3C18-MS-II (2.5 μm particle size, 2.0 mm I.D. × 50 mm; Nacalai Tesque, Inc.), and the mobile phase consisted of water containing 0.1% formic acid (Solution A) and acetonitrile containing 0.1% formic acid (Solution B). The solution was pumped at 0.4 mL / min. Initially, 5% Solution B was pumped through the column. The concentration was increased to 15% Solution B between 0.3 and 2.5 minutes, then to 95% Solution B between 2.5 and 3.5 minutes, and then pumped at 95% Solution B between 3.5 and 4 minutes. The concentration was then returned to 5% Solution B by 4.1 minutes, and the solution was pumped as is until 5.5 minutes. Angiotensin III was detected by mass spectrometry using a precursor ion at m / z 466.3 and a product ion at m / z 70.1. The results are shown in Figure 2 and Table 1.

[0047]

[0048] (2) Hydrolytic activity of Glu-MCA The post-dialysis sample solutions of various APA-Fc fusion proteins obtained in Test 1 above were diluted 10,000-fold in a buffer (pH 7.5) containing 25 mM trishydroxymethylaminomethane, 1 mM calcium chloride, and 0.01% bovine serum albumin, and the resulting APA-Fc fusion proteins were incubated at 37°C with 50 μM Glu-MCA (Watanabe Chemical Industry Co., Ltd.), in which the carboxyl group of Glu was fluorescently labeled with methylcoumarinamide. Fluorescence (excitation wavelength 370 nm / emission wavelength 460 nm) derived from 7-amino-4-methylcoumarin produced by hydrolysis of Glu-MCA was detected over time using a plate reader (Spark 10M, Tecan Japan). A calibration curve was created from the fluorescence intensity when a solution of 7-amino-4-methylcoumarin (Tokyo Chemical Industry Co., Ltd.) of known concentration was used as a standard sample, and the amount of 7-amino-4-methylcoumarin produced by hydrolysis was quantified. The results are shown in Figure 3. In addition, a calibration curve was created from AMC produced by incubation with Glu-MCA using various APA-Fc fusion proteins of known concentrations as standard samples, and the concentrations of various APA-Fc fusion proteins in plasma samples were quantified.

[0049] As shown in Figure 2 and Table 1, among the APA-Fc fusion proteins, those employing (G4S), (G4S)2, (G4S)3, (EA3K), and (EA3K)3 as linkers had higher hydrolytic activity for angiotensin II, a physiological substrate of APA, compared to rhAPA-Fc (no linker). On the other hand, as shown in Figure 3, among the APA-Fc fusion proteins, those employing (G4S), (G4S)2, (G4S)3, and (EA3K)3 as linkers had slightly higher hydrolytic activity for Glu-MCA, another substrate of APA, compared to rhAPA-Fc (no linker). It was found that the increase in enzyme activity due to the introduction of a linker depends on the linker sequence and the substrate compound.

[0050] [Test 3] 125 Evaluation of fetal transfer of I-labeled APA-Fc fusion protein in pregnant mice. 83.3 pM of APA-Fc fusion protein (rhAPA-Fc) was added to 3.7 MBq of Na in 50 mM phosphate buffer (pH 7.5).125 I and 50 μg / mL chloramine T were added, and the reaction was allowed to proceed at room temperature for 2 minutes. After that, 85 μg / mL cysteine ​​was added to terminate the reaction. The reaction solution was applied to a PD MidiTrap G-25 (Cytiva) equilibrated with PBS containing 0.1% bovine serum albumin, and the eluate was collected. The radioactivity of the eluate was measured using a gamma counter (ARC-8001, Nippon Raytec Co., Ltd.), and the highly radioactive fraction (4.98 × 10 5 18-day-old pregnant ICR mice (Japan SLC Co., Ltd.) were anesthetized with isoflurane and administered [ 125 I] rhAPA-Fc 4×10 6 dpm / kg was administered via the jugular vein, and the mice were euthanized and fetuses were collected 1, 5, and 120 minutes later. Ice-cold PBS (3 times the weight of the fetuses) was added and the mixture was homogenized. Bovine serum albumin and trichloroacetic acid were added to final concentrations of 0.12% and 15%, respectively, and the mixture was centrifuged at 6,700 g for 1 minute. The radioactivity of the precipitate was measured using a gamma counter. The results are shown in Table 2.

[0051]

[0052] As shown in Table 2, 125 Even 120 minutes after administration of the I-labeled APA-Fc fusion protein rhAPA-Fc, radioactivity detected in the fetus was 0.5% or less of the total administered dose, suggesting that the transfer of rhAPA-Fc to the fetus in mice is extremely low.

[0053] [Test 4] Evaluation of the blood stability of various APA-Fc fusion proteins in mice. Seven-week-old ICR female mice (Japan SLC, Inc.) were anesthetized with isoflurane and administered a single intravenous dose of 6.92 mg / kg of various APA-Fc fusion proteins dissolved in PBS containing 0.1% BSA via the jugular vein. Blood collected from the tail vein was centrifuged at 6,200 g at room temperature for 5 minutes to obtain plasma. Plasma samples were incubated with Glu-MCA, and the fluorescence derived from the generated 7-amino-4-methylcoumarin was detected using a plate reader (see Test 2 above). Pharmacokinetic parameters were calculated from moment analysis of the plasma concentration profiles of various APA-Fc fusion proteins. The results are shown in Figure 4 and Table 3.

[0054]

[0055] As shown in Figure 4 and Table 3, among the APA-Fc fusion proteins, those employing (G4S), (G4S)2, and (G4S)3 had higher stability in blood compared to rhAPA-Fc (without a linker). On the other hand, those employing (EA3K), (EA3K)2, and (EA3K)3 as the linker showed stability in blood comparable to or slightly higher than that of linker-free rhAPA-Fc immediately after administration, but were found to be less stable than rhAPA-Fc after 8 hours or more after administration.

[0056] [Test 5] Evaluation of the Antihypertensive Effect of Various APA-Fc Fusion Proteins The antihypertensive effect of rhAPA-Fc was evaluated in mice in which hypertension was transiently induced by administration of angiotensin II. Seven-week-old female C57BL6 mice (Japan SLC Co., Ltd.) were anesthetized with intraperitoneal administration of ketamine (200 mg / kg) and administered rhAPA-Fc (6.92 mg / kg) or vehicle (PBS pH 7.5 containing 0.1% BSA) intrajugularly. 20 minutes later, angiotensin II (0.5 mg / kg) was administered intraperitoneally. Systolic blood pressure was measured over time using a non-invasive sphygmomanometer (BP-98AL, Softron Co., Ltd.) by the tail-cuff method. The test scheme is shown in Figure 5, and the results are shown in Figure 6.

[0057] As shown in Figure 6, among the APA-Fc fusion proteins, those employing (G4S), (G4S)3, and (EA3K)3 as linkers exhibited superior antihypertensive effects compared to rhAPA-Fc (without a linker). In particular, (G4S) exhibited a significant antihypertensive effect immediately after angiotensin II administration, and this effect was sustained. Those employing (EA3K)3 as a linker gradually reduced blood pressure after angiotensin II administration, and this effect was sustained. While (EA3K)2 exhibited an effect similar to that of rhAPA-Fc (without a linker), (EA3K) exhibited an effect similar to that of PBS (negative control), showing almost no antihypertensive effect.

[0058] [Test 6] Evaluation of the Antihypertensive Effect of APA-Fc Fusion Protein To evaluate whether rhAPA-Fc(G4S)3, which has been shown to inactivate Ang II in vivo, can improve the pathology of pregnancy-induced hypertension, the effects of administration of rhAPA-Fc(G4S)3 on blood pressure, fetal number, and fetal weight were evaluated in a pregnancy-induced hypertension model mouse. Specifically, the peritoneum of 10.5-day-old ICR female mice (Japan SLC Co., Ltd.) was incised under isoflurane anesthesia, and the abdominal aorta and vena cava were partially constricted with a plastic tube (inner diameter 1.2 mm, outer diameter 2.2 mm). Under isoflurane anesthesia, rhAPA-(G4S)3-Fc (4 mg / kg) or vehicle (PBS pH 7.5 containing 0.1% BSA) was administered via the tail vein on days 15.5 and 16.5 of pregnancy. On day 17.5 of pregnancy, systolic blood pressure was measured by the tail-cuff method using a non-invasive blood pressure monitor (BP-98AL, Softron Co., Ltd.), and then the mice were euthanized, and the number of fetuses and placental weight were measured.

[0059] As shown in Figure 7, the systolic blood pressure in the vehicle-administered group increased from 105.7 ± 7.6 mmHg on day 10.5 of pregnancy, just before partial stenosis of the abdominal aorta and vein, to 123.7 ± 13.7 mmHg on day 17.5 of pregnancy after stenosis, demonstrating successful production of a gestational hypertension mouse model. On the other hand, the rhAPA-(G4S)3-Fc-administered group showed no increase in systolic blood pressure, with a pre-stenosis value of 101.1 ± 3.7 mmHg and a post-stenosis value of 99.0 ± 14.2 mmHg, a value significantly lower than that of the vehicle-administered group. These results suggest that rhAPA-(G4S)3-Fc can suppress increases in maternal systolic blood pressure in this gestational hypertension mouse model.

[0060] To evaluate the effects of rhAPA-(G4S)3-Fc on fetuses in a mouse model of gestational hypertension, placental weight, believed to be derived from the fetus, was evaluated. The placental weight in the vehicle-administered group was 123±6 mg, while that in the rhAPA-(G4S)3-Fc-administered group was 137±13 mg, demonstrating a significant increase in placental weight due to administration of rhAPA-(G4S)3-Fc. The fetal fat percentage in the mouse model of gestational hypertension was calculated by comparing the number of fetuses on day 10.5 of pregnancy before stenosis with that on day 17.5 of pregnancy after stenosis. The results were 14.3±21.8% in the vehicle group and 5.9±10.0% in the rhAPA-(G4S)3-Fc-administered group, demonstrating a trend toward a decrease in fetal mortality in the mouse model of gestational hypertension. These results suggest that rhAPA-(G4S)3-Fc can improve fetal development in this mouse model of pregnancy-induced hypertension, and that it may have therapeutic effects on both the mother and the fetus in treating pregnancy-induced hypertension.

[0061] The amino acid sequences of SEQ ID NOs: 1 to 12 are as follows:

[0062] SEQ ID NO: 1: MSALLILALVGAAVA

[0063] SEQ ID NO: 2: MSALLILALVGAAVAGTAQDQDICPASEDESGQWKNFRLPDFVNPVHYDLHVKPLLEEDTYTGTVSISINLSAPTRYLWLHLRETRITRLPELKRPSGDQVQVRRCFEYKKQEYVVVEAEEELTPSSGDGLYLLTMEFAGWLNGSLVGFYRTTYTENGQVKSIVATDHEPTDARKSFPCFDEPNKKATYTISITHPKEYGALSNMPVAKEESVDDKWTRTTFEKS VPMSTYLVCFAVHQQFDSVKRISSNSGKPLTIYVQPEQKHTAEYAANITKSVFDYFEEYFAMNYSLPKLDKIAIPDFGTGAMENWGLITYRETNLLYDPKESASSNQQRVATVVA HELVHQWFGNIVTMDWWEDLWLNEGFASFFEFLGVNHAETDWQMRDQMLLEDVLPVQEDDSLMSSHPIIVTTPDEITSVFDGISYSKGSSILRMLEDWIKPENFQKGCQMY LEKYQFKNAKTSDFWAALEEASRLPVKEVMDTWTRQMGYPVLNVNGVKNITQKRFLLDPRANPSQPPSDLGYTWNIPVKWTEDNITSSVLFNRSEKEGITLNSSNPSGNAFLK INPDHIGFYRVNYEVATWDSIATALSLNHKTFSSADRASLIDDAFALARAQLLDYKVALNLTKYLKREENFLPWQRVISAVTYIISMFEDDKELYPMIEEYFQGQVKPIADSL GWNDAGDHVTKLLRSSVLGFACKMGDREALNNASSLFEQWLNGTVSLPVNLRLLVYRYGMQNSGNEISWNYTLEQYQKTSLAQEKEKLLYGLASVKNVTLLSRYLDLLKDTNL IKTQDVFTVIRYISYNSYGKNMAWNWIQLNWDYLVNRYTLNNRNLGRIVTIAEPFNTELQLWQMESFFAKYPQAGAGEKPREQVLETVKNNIEWLKQHRNTIREWFFNLLESG

[0064] SEQ ID NO: 3: LINHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGT

[0065] SEQ ID NO: 4: GGGGS

[0066] SEQ ID NO: 5: GGGGSGGGGS

[0067] SEQ ID NO: 6: GGGGSGGGGSGGGGGS

[0068] SEQ ID NO: 7: EAAAK

[0069] SEQ ID NO: 8: EAAAKEAAAK

[0070] SEQ ID NO: 9: EAAAKEAAAKEAAAK

[0071]

[0072]

[0073]

[0074] The preventive / therapeutic agent for pregnancy-induced hypertension of the present invention contains as an active ingredient a fusion protein (APA-Fc fusion protein) in which aminopeptidase A (APA) is bound to an immunoglobulin Fc region via a peptide linker. This fusion protein exhibits pharmacological effects that mimic the physiological functions of the placenta and is highly safe for the mother. Furthermore, the physical properties and molecular weight of the APA-Fc fusion protein prevent it from penetrating the placental barrier, ensuring excellent safety for the fetus. Furthermore, the APA-Fc fusion protein has a structure in which APA is bound to an immunoglobulin Fc region via a specific peptide linker. This structure provides an excellent pharmacological effect of degrading angiotensin II to lower blood pressure, and the fusion protein is able to maintain its effectiveness for a long period of time in the body, making it suitable for use as a preventive / therapeutic agent for pregnancy-induced hypertension.

Claims

1. A preventive / therapeutic agent for pregnancy-induced hypertension, comprising aminopeptidase A (APA) as an active ingredient, characterized in that the APA is linked to an immunoglobulin Fc region via a peptide linker.

2. The preventive / therapeutic agent for pregnancy-induced hypertension according to claim 1, wherein the peptide linker consists of 5 to 60 amino acids.

3. The preventive / therapeutic agent for pregnancy-induced hypertension according to claim 1 or 2, wherein the peptide linker comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 4 to 9.

4. The preventive / therapeutic agent for pregnancy-induced hypertension according to claim 3, further comprising a pharma-ceutical acceptable carrier.

5. Aminopeptidase A (APA)-Fc fusion protein in which APA is linked to an immunoglobulin Fc region via a peptide linker comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 10-12.

6. The APA-Fc fusion protein of claim 5 having the amino acid sequence shown in SEQ ID NO:11.

Citation Information

Patent Citations

  • Therapeutic agent

    JP2007217395A

  • HM-3 fusion protein and its applications

    JP2021505593A

  • Composition for preventing or treating immune-related diseases

    JP2021532119A

  • Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes

    WO2021221482A1